Skip to main content
Caplight Logo









NiKang Therapeutics

NiKang Therapeutics

Private
Wilmington, DelawareHealthcare & Life Scienceshttps://www.nikangtx.com/

Last Round

Series C

May 26, 2021

Total Funding Raised

$270M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NiKang Therapeutics is a biotechnology company that discovers and develops innovative small molecule oncology medicines to address unmet medical needs through structure-based drug design.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

small molecule drugsoncology therapeuticsstructure-based drug designtargeted oncologyHIF2α inhibitorundruggable targetsKRAS inhibitorCDK2 inhibitorCDK2 degradersolid tumor therapyclinical-stage biotechPROTAC degraderclear cell renal cell carcinomaccRCCbiotech licensingSHP2 inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NiKang Therapeutics Comparables

Compare NiKang Therapeutics with similar companies based on industry and business-model similarity.

NiKang Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avenzo Therapeutics
78%
Arcus Biosciences
77%
Novartis
74%

NiKang Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 26, 2021
Series BSep 14, 2020
SeedDec 4, 2017

Key People

Founding team and executive leadership

Kelsey Chen

CFO COO, Chief Financial Officer

Executive Team

NiKang Therapeutics Investors

Notable investors and investment history

NiKang Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries C
MatrixSeries B, Series C
Surveyor CapitalSeries C
Janus Henderson GroupSeries C
RA Capital ManagementSeries C
Perceptive AdvisorsSeries C
Octagon Capital AdvisorsSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 47% MoM.

  • Jun 18, 2026

    Monthly visitors increased 96% MoM.

NiKang Therapeutics Filings

Explore SEC and related filing metadata, where available.

NiKang Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NiKang Therapeutics's valuation, stock price, and market status.

Is NiKang Therapeutics a public or private company?

NiKang Therapeutics is a private company.

What is the current stock price of NiKang Therapeutics?

NiKang Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NiKang Therapeutics worth (valuation)?

Valuation information for NiKang Therapeutics is not publicly available.

Can I buy NiKang Therapeutics stock?

NiKang Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NiKang Therapeutics's last funding round?

NiKang Therapeutics's most recent funding round was Series C on May 26, 2021.

Who are the main investors in NiKang Therapeutics?

Key investors in NiKang Therapeutics include Octagon Capital Advisors, CBC Group, HBM Healthcare Investments, Cormorant Asset Management.

Will NiKang Therapeutics IPO soon?

No public IPO plans have been announced for NiKang Therapeutics.

How can I track NiKang Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NiKang Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWilmington, Delaware
Employee Range36
Year Founded2017
Last FundingMay 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?